Impact of COVID-19 on the Benefit of Cardiac Rehabilitation (REACARDIOCOVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04513964|
Recruitment Status : Recruiting
First Posted : August 14, 2020
Last Update Posted : December 31, 2020
The COVID-19 attack is polymorphic with otorhinolaryngological, pneumological, cardiac, digestive, neurological, muscular attacks with a higher mortality in subjects with comorbidity [> 70 years old, cardiovascular history in particular Arterial hypertension (hypertension ), heart disease…]. This polymorphism is linked to vasculitis and the immune response.
Patients with cardiovascular disease are particularly at risk of decompensating, particularly due to the increased metabolism induced by viral infection and reduced cardiovascular capacities.
On the cardiovascular level, two sides can be considered. On the one hand, cardiovascular disease (hypertension, coronary artery disease) is a comorbid factor. On the other hand, the myocardial damage reflected by the increase in troponin or an alteration of the ejection fraction is a very clear risk factor for death or severe form.
Cardiovascular involvement is particularly high in hospitalized and deceased patients. The odds ratio calculated in a meta-analysis of severe forms of covid-19 with hypertension is 3 [1.9; 3.1], for cardiovascular pathologies of 2.93 [1.73; 4.96]. Recommendations were made for pulmonary rehabilitation but not for cardiovascular rehabilitation.
Cardiac rehabilitation is indicated in most cardiovascular pathologies (after acute coronary syndrome, after coronary angioplasty, in heart failure, after coronary or valve heart surgery, etc.).
It consists of a multidisciplinary approach combining therapeutic pharmacological adjustment, physical activity, therapeutic education in order to improve physical capacities for exertion and reduce morbidity and mortality. The physical exercises can be endurance or resistance type.
Capacity gain at the end of rehabilitation is measured by visual scales, quality of life questionnaires, and a stress test at the start and end of rehabilitation. Most often, rehabilitation centers only do the stress test and estimate through questioning for subjective improvement.
The hypothesis is that patients who contracted COVID-19 would have lower cardiac capacities after recovery from the infection than patients without COVID-19 or that their capacity for recovery would be less. There could be a difference in recovery after cardiac rehabilitation between the two populations regardless of whether the cardiac damage requiring rehabilitation was triggered by COVID-19 or was pre-existing.
|Condition or disease|
|Heart Failure Covid19|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Impact of COVID-19 on the Benefit of Cardiac Rehabilitation|
|Actual Study Start Date :||November 1, 2020|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||June 30, 2021|
Patient not suffering from COVID-19
Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
- Impact of COVID-19 on exercise capacity gain after cardiovascular rehabilitation [ Time Frame: Month 3 ]This outcome corresponds to the difference between the average gain in exercise capacity after cardiac rehabilitation between the two groups of patients Control and COVID-19.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04513964
|Contact: DUC Philippe, MD||0144127883 ext +email@example.com|
|Contact: BEAUSSIER Helene, PharmD, pHD||0144127883 ext +firstname.lastname@example.org|
|Groupe Hospitalier Paris Saint-Joseph||Recruiting|
|Paris, Groupe Hospitalier Paris Saint-Joseph, France, 75014|
|Contact: Philippe DUC, MD email@example.com|
|Hôpital Corentin Celton||Not yet recruiting|
|Issy-les-Moulineaux, France, 92130|
|Contact: Iliou Marie-Christine, MD firstname.lastname@example.org|
|Study Director:||DUC Philippe, MD||Groupe Hospitalier Paris Saint Joseph|